Investigational Drug Information for TL-895
✉ Email this page to a colleague
What is the drug development status for TL-895?
TL-895 is an investigational drug.
There have been 7 clinical trials for TL-895.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 22nd 2020.
The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, and Thrombocytosis. The leading clinical trial sponsors are Telios Pharma, Inc., Kartos Therapeutics, Inc., and Merck KGaA.
There are five US patents protecting this investigational drug and fifty-nine international patents.
Summary for TL-895
| US Patents | 5 |
| International Patents | 59 |
| US Patent Applications | 21 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 1 (2020-10-22) |
| Vendors | 17 |
Recent Clinical Trials for TL-895
| Title | Sponsor | Phase |
|---|---|---|
| Phase 1b/2 Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | Telios Pharma, Inc. | Phase 1/Phase 2 |
| Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | Kartos Therapeutics, Inc. | Phase 2 |
| TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Kartos Therapeutics, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for TL-895
Top disease conditions for TL-895
Top clinical trial sponsors for TL-895
US Patents for TL-895
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TL-895 | ⤷ Sign Up | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| TL-895 | ⤷ Sign Up | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| TL-895 | ⤷ Sign Up | Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| TL-895 | ⤷ Sign Up | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| TL-895 | ⤷ Sign Up | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | Merck Patent GmbH (Darmstadt, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TL-895
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TL-895 | Australia | AU2012267491 | 2031-06-10 | ⤷ Sign Up |
| TL-895 | Australia | AU2017235978 | 2031-06-10 | ⤷ Sign Up |
| TL-895 | Brazil | BR112013030442 | 2031-06-10 | ⤷ Sign Up |
| TL-895 | Canada | CA2833771 | 2031-06-10 | ⤷ Sign Up |
| TL-895 | China | CN103814016 | 2031-06-10 | ⤷ Sign Up |
| TL-895 | China | CN106831732 | 2031-06-10 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
